April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Radical: 24-month Results Of A Phase II Exploratory Randomized Clinical Trial Of Reduced-fluence vPDT-anti-VEGF-dexamethasone In AMD
Author Affiliations & Notes
  • Henry L. Hudson
    Retina Centers PC, Tucson, Arizona
  • RADICAL Study Group
    Retina Centers PC, Tucson, Arizona
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3527. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Henry L. Hudson, RADICAL Study Group; Radical: 24-month Results Of A Phase II Exploratory Randomized Clinical Trial Of Reduced-fluence vPDT-anti-VEGF-dexamethasone In AMD. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3527.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine if combined therapy with reduced-fluence vPDT followed by ranibizumab and dexamethasone reduces retreatment rates compared with ranibizumab monotherapy in subjects with CNV secondary to AMD while maintaining similar vision outcomes and acceptable safety.

Methods: : Subjects were randomized to 1 of 4 treatment groups: 1) quarter-fluence triple therapy (vPDT 15 J/cm2+ranibizumab 0.5 mg + dexamethasone 0.5 mg; 2) half-fluence triple therapy (vPDT 25 J/cm2 + ranibizumab + dexamethasone); 3) half-fluence vPDT + ranibizumab; or 4) ranibizumab monotherapy. Inclusion criteria were ≥ 50 years, subfoveal choroidal neovascularization from AMD, naïve to treatment, visual acuity (VA) letter score 73-25 (approximate Snellen equivalent of 20/40 - 20/320), and lesion ≤ 5400 microns. Combination groups had 1 mandatory treatment; ranibizumab monotherapy had 3. Central retinal thickness and fluorescein angiography determined retreatment after mandatory treatment.

Results: : 162 subjects were enrolled. Through Month 24, the cumulative number of combination retreatments was 5.9 (P=.03), 4.3 (P<.001), 5.9 (P=.02), and 8.7 (P value comparing ranibizumab monotherapy) in groups 1, 2, 3, and 4, respectively. Month 24 VA letter score change from baseline (95% confidence interval) was -0.2 (-5.7 to +5.4), +1.1 (-4.3 to +6.4), -0.3 (-6.2 to +5.6), and +4.4 (-1.5 to +10.2), respectively. In the combination groups 5 subjects had serious ocular events considered associated with treatment (increased intraocular pressure, retinal tear, decreased vision, vitreous hemorrhage and retinal/vitreous detachment).

Conclusions: : Combination groups had fewer retreatment visits. The triple therapy half-fluence group (group 2) had half the number of retreatment visits required of the ranibizumab monotherapy group. In the second year it was one third. Mean VA change from baseline was not statistically different among the treatment groups, although the sample sizes were insufficient to draw definitive conclusions whether visual acuity outcomes were better or worse in any of the combination groups compared with the ranibizumab monotherapy group. In the second year, overall AE rates remain similar among groups with no new safety concerns.

Clinical Trial: : http://www.clinicaltrials.gov NCT00492284

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×